BioSpace News Archive

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) today announced that it will release financial results for the first quarter ended March 31, 2023, before the stock market opens on Monday, May 15, 2023.

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter ended March 31, 2023, after the market closes on May 15, 2023.

ARS Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration posted briefing documents for the Pulmonology, Allergy-Drugs Advisory Committee meeting to review the new drug application for neffy®.

Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant in its pivotal clinical trial investigating oral weekly risperidone (LYN-005).

Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or “Company”) today announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study evaluating the investigational use of TREMFYA® (guselkumab) in adults with moderately to severely active ulcerative colitis (UC)a who had an inadequate response or intolerance to conventionalb and/or advanced therapies.

Hubly Surgical announced today that they received 510k clearance from the FDA to market the Hubly Drill, an innovative medical technology developed with the goal of making burr hole procedures safer and more efficient in any setting, including outside of the operating room.

Turn Biotechnologies announced that Chief Executive Officer, Anja Krammer, will present an updated corporate overview at the JMP Securities Life Sciences Conference in New York City being held May 15th-16th, 2023 in New York City.

Anthos Therapeutics presented details of the development of a novel patient-reported outcome assessment scale to measure the patient relevant burden of oral anticoagulant treatment at ISPOR—The Professional Society for Health Economics and Outcomes Research’s annual meeting, held in Boston, May 7-10, 2023.

Hemogenyx Pharmaceuticals plc announces the submission of an Investigational New Drug (“IND”) application seeking authorization from the U.S. Food and Drug Administration (“FDA”) to begin a Phase I clinical trial of its lead product candidate Chimeric Antigen Receptor (“CAR”) T-cells (“HEMO-CAR-T”) for treating acute myeloid leukemia (AML).